Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

NCT05303376 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
123
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Immune Biosolutions Inc